Abstract
AbstractAn unprecedented number of human infections with avian influenza A(H7N9) in the fifth epidemic wave during the winter of 2016–2017 in China and their antigenic divergence from the viruses that emerged in 2013 prompted development of updated vaccines for pandemic preparedness. We report on the findings of a clinical study in healthy adults designed to evaluate the safety and immunogenicity of three dose levels of recombinant influenza vaccine derived from highly pathogenic A/Guangdong/17SF003/2016 (H7N9) virus adjuvanted with AS03 or MF59 oil-in water emulsions. Most of the six study groups meet the FDA CBER-specified vaccine licensure criterion of 70% seroprotection rate (SPR) for hemagglutination inhibition antibodies to the homologous virus. A substantial proportion of subjects show high cross-reactivity to antigenically distinct heterologous A(H7N9) viruses from the first epidemic wave of 2013. These results provide critical information to develop a pandemic response strategy and support regulatory requirements for vaccination under Emergency Use Authorization.
Funder
U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference32 articles.
1. Gao, R. et al. Human infection with a novel avian-origin influenza A(H7N9) virus. N. Engl. J. Med. 368, 1888–1897 (2013).
2. Liu, D. et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 381, 1926–1932 (2013).
3. Yang, J. R. & Liu, M. T. Human infection caused by an avian influenza A(H7N9) virus with a polybasic cleavage site in Taiwan, 2017. J. Formos. Med. Assoc. 116, 210–212 (2017).
4. Yang, L. et al. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in Mainland China.J. Virol. 91, e01277-17 (2017).
5. WHO. Antigenic and Genetic Characteristics of Zoonotic Influenza Viruses and Development of Candidate Vaccine Viruses for Pandemic Preparedness, http://www.who.int/influenza/vaccines/virus/201703_zoonotic_vaccinevirusupdate.pdf?ua=1 (2017).